- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Restaurant Group Sues Over Salt Warnings
What we're reading, December 4, 2015: restaurant group sues New York City over salt warnings rule; Turing CEO remains unapologetic over Daraprim price hike; and women face a higher risk of needing costly, long-term care.
Salt Warning Rule Leads to Lawsuit in NYC
The National Restaurant Association is suing New York City over a rule that would require many restaurants to post warnings on menus next to items that are high in sodium. The rule would warm diners about foods with more than the daily recommended limit of sodium. The rule took effect on Tuesday and effects restaurants with more than 15 locations nationwide, and some movie theaters and sports stadiums. Violators would be punished by a $200 fine.
Shkreli Unapologetic About Daraprim Price Hike
Despite public disapproval of the new high cost of Daraprim, Turing Pharmaceuticals CEO Martin Shkreli remains unapologetic about the increase. Although the company cut the cost of Daraprim by 50% for hospitals, insurers and some patients still have to pay the full $750 per tablet list price. STAT reported that at the Forbes Health Summit, Shkreli defended the 5000% price hike by explaining his investors expect him to “maximize profits.”
Women Face Higher Risk of Needing Costly, Long-Term Care
Long-term care is costly, but the likelihood of needing such care after the age of 65 years if you are a woman is especially high, according to a new report. While the chances an American will need a high level of long-term supports and services are approximately 50/50, those odds increase to 6 in 10 for women. They will also need it for longer. Overall, the total cost of care for women older than age 65 years far exceeds the cost for men, Forbes reported.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
